Live Breaking News & Updates on நோயெதிர்ப்பு கண்டுபிடிப்பு
Stay updated with breaking news from நோயெதிர்ப்பு கண்டுபிடிப்பு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Published: Apr 21, 2021 - Backed by leading healthcare investors including SV Health Investors - Cambridge, UK, 20 April 2021 – Mestag Therapeutics (“Mestag”), a breakthrough inflammatory disease and immuno-oncology company, today announced its launch with $11 million seed financing from healthcare investors SV Health Investors and Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”). The Company’s mission is to develop new medicines for patients by targeting activated fibroblast populations and their role in influencing immune effector cells in disease. Powerful new technologies enable diseased tissues to be analyzed at a single-cell level, and this work has uncovered discrete fibroblast cell sub-populations shared across diseases, acting as “immune sentinels” in perpetuating, and progressing disease. Mestag is building a pipeline of first in class therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory disease and im ....
argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for efgartigimod in generalized myasthenia gravis (gMG) Initiated 50-patient gMG bridging study of subcutaneous (SC) efgartigimod based on FDA feedback Enrolled first 30 patients, necessary for go/no-go decision, in ADHERE trial of SC efgartigimod for chronic inflammatory demyelinating polyneuropathy (CIDP) Announced interim data from Phase 2 CULMINATE trial of cusatuzumab in development with Janssen Breda, the Netherlands – Jan. 8, 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancers, today announced its 2021 corporate priorities and highlighted re ....